Previous | Home | Next

9. JDC Updates

JPEF: 24 October 2015

The new SGLT2 inhibitor Empagliflozin was launched in Trivandrum at Jothydev’s Professional Education CME conducted at Vivanta by Taj, Trivandrum on 24th October 2015. The CME had Dr.K.M Prasanna Kumar, as one of the speakers. Dr.Prasanna Kumar lectured on Empagliflozin-relating the theory of extra glycemic effects to clinical practice. Dr.Jothydev Kesavadev lectured on the much discussed Empa-Reg Outcome study, improving survival in type 2 diabetes. Dr.Shradda Bhure lectured on the next generation SGLT2 inhibitor.

The CME had senior doctors including Dr.Balachandran, Dr.Ramesan Pillai, Dr.Vasudevan Potty, Dr.Thomas Titus etc. participating actively in the discussions which followed the lectures. .

More pictures

Uttarkhand Convocation Oration: 10-11 October 2015
Dr. Jothydev Kesavadev has been conferred Fellowship by the Uttar Pradesh Diabetes Association(UPDA) for his outstanding contributions to original research in diabetes in India. The Fellowship has been awarded by UPDA President Dr. Anuj Maheswari and Uttarakhand Open University Vice Chancellor Dr. Subhash Dhulia at the 14th Annual Convention of UPDA at Uttarakhand, Nainital. Following the convocation Dr.Jothydev Kesavadev delivered an oration on how the emerging technologies in diabetes can help reduce the long term cost and complications in diabetes.
 
More pictures
Previous | Home | Next
Share/Bookmark
This newsletter is published for free distribution through the Internet for doctors, patients and public for promoting healthy lifestyles.
For enquiries info@jothydev.net.
Please visit: jothydev.net | research.jothydev.com | diabscreenkerala.net | jothydev.com/newsletter